CAPR, | Page 2 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

0

content_middle

content_right

November 16, 2015 - 10:34am | Earnings Q3
Regenerative Medicine Earnings Scorecard - Q3/2015
October 6, 2015 - 7:03am | Research Notes, Financings
Capricor Therapeutics (CAPR) the parent not the subsidiary will be responsible for debt
September 28, 2015 - 9:32am | Research Notes, Financings
Capricor (CAPR) gets ready for a financing
June 8, 2015 - 10:06am | Regulatory, Research Notes
Capricor (CAPR) starting P1/2 Study of CAP-1002 used for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy in Q3/15 - Strong SELL, it’s slipping fast after a positive open
April 22, 2015 - 11:37am | Regulatory
Capricor’s (CAPR) Duchenne Treatment gets FDA Orphan Drug Designation - SELL
April 8, 2015 - 8:35am | Regulatory
Capricor (CAPR) Completes initial enrollment DYNAMIC clinical trial
March 31, 2015 - 8:40am | Regulatory
Capricor Therapeutics (CAPR) Completes Enrollment of P2 trial for Cenderitide to treat heart failure
March 5, 2015 - 10:58am | Out and About
Capricor Therapeutics (CAPR) up-listed to NASDAQ Capital Market
February 27, 2015 - 9:31am | BOD & C-Suite Updates
Capricor Therapeutics (CAPR) New VP of Regulatory Affairs and Drug Development
February 4, 2015 - 10:30am | Financings
Capricor Therapeutics (OTCBB: CAPR) $7 M Private Placement
January 23, 2015 - 9:29am | BOD & C-Suite Updates
Capricor Therapeutics (CAPR) Cedars Sinai Medical Center, reported 10% holding
January 13, 2015 - 10:15am | Research Notes
Capricor (CAPR) begins enrollment in DYNAMIC trial for treating advanced heart failure
January 12, 2015 - 10:06am | Financings
Capricor (CAPR) inks $10 M private placement agreement
November 18, 2014 - 8:56am | Regulatory
Capricor (OTCBB: CAPR) P1 ALLSTAR Safety Results
November 18, 2014 - 8:38am | Regulatory
Capricor (OTCBB: CAPR) Positive pre-clinical data for Duchenne Muscular Dystrophy
November 14, 2014 - 1:58pm | Earnings
RegMed Q3/14 Earnings Comparisons
November 13, 2014 - 11:16am | Earnings
Capricor (CAPR) Q3/14 Earnings – Loss FLAT, LPS* FLAT
November 7, 2014 - 9:14am | Research Notes
Capricor (CAPR): Duchenne Muscular Dystrophy data presentation call 11/18 at 9:30 am ET
October 31, 2014 - 10:13am | Earnings Alert
Capricor (CAPR) Q3/14 results on 11/12 at 4:30 pm ET
October 16, 2014 - 2:13pm | Earnings Q3
Regenerative Medicine Earnings Scorecard - Q3/2014

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.